Rapport Therapeutics
RAPP
147 hedge funds and large institutions have $1.64B invested in Rapport Therapeutics in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 24 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 34
45% more call options, than puts
Call options by funds: $638K | Put options by funds: $441K
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6% more capital invested
Capital invested by funds: $1.55B → $1.64B (+$91.6M)
2.61% more ownership
Funds ownership: 107.18% → 109.8% (+2.6%)
2% more funds holding
Funds holding: 144 → 147 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$17.9M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$15.1M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$9.18M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.23M |
| 5 |
SCM
Sio Capital Management
New York
|
+$5.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$8.57M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$3.94M |
| 3 |
Renaissance Technologies
New York
|
-$3.07M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$2.68M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.6M |
RAPP Hedge Fund Activity: Q1 2026 in Review
147 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q1 2026, worth a combined $1.64B — up 5.9% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RAPP positions and 24 closed out — a net gain of 6 holders — while 53 added to existing stakes and 34 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $17.9M. The largest seller was Capital International Investors, cutting an estimated $8.57M.
- 147 institutional investors held Rapport Therapeutics (RAPP) as of Q1 2026, up from 144 in Q4 2025.
- Funds reported $1.64B of Rapport Therapeutics stock for Q1 2026, up 5.9% quarter-over-quarter.
- 30 funds opened new Rapport Therapeutics positions in Q1 2026 and 24 closed out, a net change of +6 holders.
- The largest Rapport Therapeutics buyer in Q1 2026 was Polar Capital Holdings, an estimated $17.9M added.
- The largest Rapport Therapeutics seller in Q1 2026 was Capital International Investors, an estimated $8.57M sold.
Based on aggregated 13F filings for Q1 2026.